Exela Technologies, Inc. Reports Full Year and Fourth Quarter 2022 Results
#Business
Full Year Highlights
- 2022 revenue of
$1,077.2 million , down 7.7% year-over-year (5.7% on a constant currency basis) - Net loss of
$415.6 million , includes non-cash goodwill impairment charges of$171.2 million - Implemented actions expected to achieve savings in the range of
$65-$75 million beginning in Q4 2022 and into 2023 - Total debt(1) reduced by
$141.1 million
Fourth Quarter Highlights
- Revenue of
$267.0 million , down 9.3% year-over-year (7.3% on a constant currency basis) - Net loss of
$194.1 million , includes non-cash goodwill impairment charges of$141.6 million
Conference call scheduled for
“We continue to make operational improvements across the organization in the face of heightened inflation and the evolving hybrid work environment. Exelarators are working nonstop to offer the best solutions for customers. Internally, we are also focusing on continuing to improve the balance sheet and lowering our cost of capital, even as rates are driven higher by central banks. It’s been a tough, but productive year,” said Par Chadha, Executive Chairman of
Full Year Highlights
- Revenue: Revenue for 2022 was
$1,077.2 million , a decline of 7.7% compared to$1,166.6 million in 2021 due to rising costs, a tight job market, business mix, rising dollar and onetime events.- Revenue for the Information and Transaction Processing Solutions (“ITPS”) segment was
$765.1 million , a decline of 12.5% year-over-year, primarily due to a network outage(2) impacting contracted revenues, currency translation, and staffing shortages. - Healthcare Solutions revenue was
$239.3 million , an increase of 9.9% year-over-year, led by continuing acceptance of our solutions and services. - Legal and
Loss Prevention Services revenue was$72.8 million , a decrease of 2.4% year-over-year.
- Revenue for the Information and Transaction Processing Solutions (“ITPS”) segment was
Operating income/(loss): Operating loss for 2022 was
- Net Loss: Net loss for 2022 was
$415.6 million , compared with a net loss of$142.4 million in 2021. The year over year increase was primarily due to the changes in the operating loss including goodwill impairment charges and changes in non-cash debt extinguishment charges. Additionally, we implemented actions expected to achieve savings in the range of$65-$75 million beginning in Q4 2022 and into 2023.
- EBITDA(3): EBITDA for 2022 was a loss of
$174.7 million compared to$114.5 million in 2021. EBITDA margin for 2022 was (16.2%) compared to 9.8% in 2021. - Adjusted EBITDA(4): Adjusted EBITDA for 2022 was
$139.9 million , a decrease of 19.3% compared to$173.3 million in 2021. Adjusted EBITDA margin for 2022 was 13.0%, a decrease of 187 basis points from 14.9% in 2021.
- EBITDA(3): EBITDA for 2022 was a loss of
- Capital Expenditures: Capital expenditures for 2022 were 2.0% of revenue compared to 1.4% of revenue in 2021.
Maintaining financial flexibility: Raised a total of
Fourth Quarter Highlights
- Revenue: Revenue for Q4 2022 was
$267.0 million , a decline of 9.3% compared to$294.3 million in Q4 2021.- Revenue for the Information and Transaction Processing Solutions (“ITPS”) segment was
$184.8 million , a decline of 14.7% year-over-year, primarily due to a network outage impacting contracted revenues, currency translation and staffing shortages. - Healthcare Solutions revenue was
$65.3 million , an increase of 15.6% year-over-year, led by continuing acceptance of our solutions and services. - Legal and
Loss Prevention Services revenue was$16.8 million , a decrease of 20.4% year-over-year.
- Revenue for the Information and Transaction Processing Solutions (“ITPS”) segment was
Operating income/(loss): Operating loss for Q4 2022 was
- Net Loss: Net loss for Q4 2022 was
$194.1 million , compared with a net loss of$70.6 million in Q4 2021. The year over year increase was primarily due to the changes in the operating loss including goodwill impairment charges.- EBITDA: EBITDA for Q4 2022 was a loss of
$135.8 million compared to a loss of$3.1 million in Q4 2021. EBITDA margin for Q4 2022 was (50.9%) compared to (1.0%) in Q4 2021. - Adjusted EBITDA: Adjusted EBITDA for Q4 2022 was
$35.5 million , a decrease of 10.2% compared to$39.5 million in Q4 2021. Adjusted EBITDA margin for Q4 2022 was 13.3%, a decrease of 14 basis points from 13.4% in Q4 2021.
- EBITDA: EBITDA for Q4 2022 was a loss of
- Capital Expenditures: Capital expenditures for Q4 2022 were 1.9% of revenue compared to 2.9% of revenue in Q4 2021.
Maintaining financial flexibility: Raised a total of
Below are the notes referenced above:
(1) Total debt includes all long-term debt and interest-bearing current liabilities
(2) In
(3) EBITDA is a non-GAAP measure. A reconciliation of EBITDA is attached to this release.
(4) Adjusted EBITDA is a non-GAAP measure. A reconciliation of Adjusted EBITDA is attached to this release.
Earnings Conference Call and Audio Webcast
Shortly after the conclusion of the call, a replay will be available through
A live webcast of this conference call will be available on the “Investors” page of the Company’s website (www.exelatech.com). A supplemental slide presentation that accompanies this call and webcast can be found on the investor relations website (http://investors.exelatech.com/) and will remain available after the call.
About
Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience. With decades of experience operating mission-critical processes, Exela serves a growing roster of more than 4,000 customers throughout 50 countries, including over 60% of the Fortune® 100. Utilizing foundational technologies spanning information management, workflow automation, and integrated communications, Exela’s software and services include multi-industry, departmental solution suites addressing finance and accounting, human capital management, and legal management, as well as industry-specific solutions for banking, healthcare, insurance, and the public sector. Through cloud-enabled platforms, built on a configurable stack of automation modules, and approximately 16,000 employees operating in 21 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner
Find out more at www.exelatech.com
To automatically receive
About Non-GAAP Financial Measures: This press release includes constant currency, EBITDA and Adjusted EBITDA, each of which is a financial measure that is not prepared in accordance with
Forward-Looking Statements: Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may”, “should”, “would”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “continue”, “future”, “will”, “expect”, “outlook” or other similar words, phrases or expressions. These forward-looking statements include statements regarding our industry, future events, estimated or anticipated future results and benefits, future opportunities for
For more
Website: https://investors.exelatech.com/
Twitter: @ExelaTech
LinkedIn: /exela-technologies
Facebook: @exelatechnologies
Instagram: @exelatechnologies
The information posted on the Company's website and/or via its social media accounts may be deemed material to investors. Accordingly, investors, media and others interested in the Company should monitor the Company's website and its social media accounts in addition to the Company's press releases, SEC filings and public conference calls and webcasts.
Investor and/or Media Contacts:
E: vincent.kondaveeti@exelatech.com
E: IR@exelatech.com
Source:
Condensed Consolidated Balance Sheets
For the years ended
(in thousands of
2022 | 2021 | ||||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 15,073 | $ | 20,775 | |||
Restricted cash | 29,994 | 27,285 | |||||
Accounts receivable, net of allowance for doubtful accounts of |
101,616 | 184,102 | |||||
Related party receivables and prepaid expenses | 759 | 715 | |||||
Inventories, net | 16,848 | 15,215 | |||||
Prepaid expenses and other current assets | 26,206 | 31,799 | |||||
Total current assets | 190,496 | 279,891 | |||||
Property, plant and equipment, net of accumulated depreciation of |
71,694 | 73,449 | |||||
Operating lease right-of-use assets, net | 40,734 | 53,937 | |||||
186,802 | 358,323 | ||||||
Intangible assets, net | 200,982 | 244,539 | |||||
Deferred income tax assets | 1,483 | 2,109 | |||||
Other noncurrent assets | 29,721 | 24,775 | |||||
Total assets | $ | 721,912 | $ | 1,037,023 | |||
Liabilities and Stockholders' Equity (Deficit) | |||||||
Liabilities | |||||||
Current liabilities | |||||||
Accounts payable | $ | 79,249 | $ | 61,744 | |||
Related party payables | 2,473 | 1,484 | |||||
Income tax payable | 2,045 | 3,551 | |||||
Accrued liabilities | 61,340 | 113,519 | |||||
Accrued compensation and benefits | 54,143 | 60,860 | |||||
Accrued interest | 60,901 | 10,075 | |||||
Customer deposits | 16,955 | 17,707 | |||||
Deferred revenue | 16,405 | 16,617 | |||||
Obligation for claim payment | 44,380 | 46,902 | |||||
Current portion of finance lease liabilities | 5,485 | 6,683 | |||||
Current portion of operating lease liabilities | 11,867 | 15,923 | |||||
Current portion of long-term debts | 154,802 | 236,775 | |||||
Total current liabilities | 510,045 | 591,840 | |||||
Long-term debt, net of current maturities | 942,035 | 1,012,452 | |||||
Finance lease liabilities, net of current portion | 9,448 | 9,156 | |||||
Pension liabilities, net | 16,917 | 28,383 | |||||
Deferred income tax liabilities | 11,180 | 11,594 | |||||
Long-term income tax liabilities | 2,742 | 3,201 | |||||
Operating lease liabilities, net of current portion | 31,030 | 41,170 | |||||
Other long-term liabilities | 6,104 | 5,999 | |||||
Total liabilities | 1,529,501 | 1,703,795 | |||||
Commitments and Contingencies (Note 14) | |||||||
Stockholders' equity (deficit) | |||||||
Common Stock, par value of |
162 | 37 | |||||
Preferred stock, |
|||||||
Series A Preferred Stock, 2,778,111 shares issued and outstanding at |
1 | 1 | |||||
Series B Preferred Stock, 3,029,900 shares issued and outstanding at |
- | ||||||
Additional paid in capital | 1,102,619 | 838,853 | |||||
Less: Common Stock held in treasury, at cost; 122,585 shares at |
(10,949 | ) | (10,949 | ) | |||
Equity-based compensation | 56,958 | 56,123 | |||||
Accumulated deficit | (1,948,009 | ) | (1,532,428 | ) | |||
Accumulated other comprehensive loss: | |||||||
Foreign currency translation adjustment | (4,788 | ) | (7,463 | ) | |||
Unrealized pension actuarial losses, net of tax | (3,583 | ) | (10,946 | ) | |||
Total accumulated other comprehensive loss | (8,371 | ) | (18,409 | ) | |||
Total stockholders' deficit | (807,589 | ) | (666,772 | ) | |||
Total liabilities and stockholders' deficit | $ | 721,912 | $ | 1,037,023 | |||
Condensed Consolidated Statements of Operations
For the years ended
(in thousands of
Years ended |
|||||||||||
2022 | 2021 | 2020 | |||||||||
Revenue | $ | 1,077,157 | $ | 1,166,606 | $ | 1,292,562 | |||||
Cost of revenue (exclusive of depreciation and amortization) | 877,474 | 889,095 | 1,023,544 | ||||||||
Selling, general and administrative expenses (exclusive of depreciation and amortization) | 176,524 | 169,781 | 186,104 | ||||||||
Depreciation and amortization | 71,831 | 77,150 | 93,953 | ||||||||
Impairment of goodwill and other intangible assets | 171,182 | - | - | ||||||||
Related party expense | 8,923 | 9,191 | 5,381 | ||||||||
Operating profit (loss) | (228,777 | ) | 21,389 | (16,420 | ) | ||||||
Other expense (income), net: | |||||||||||
Interest expense, net | 164,870 | 168,048 | 173,878 | ||||||||
Debt modification and extinguishment costs (gain), net | 4,522 | (16,689 | ) | 9,589 | |||||||
Sundry expense (income), net | (957 | ) | 363 | (153 | ) | ||||||
Other expense (income), net | 14,170 | 401 | (34,788 | ) | |||||||
Net loss before income taxes | (411,382 | ) | (130,734 | ) | (164,946 | ) | |||||
Income tax expense | (4,199 | ) | (11,656 | ) | (13,584 | ) | |||||
Net loss | $ | (415,581 | ) | $ | (142,390 | ) | $ | (178,530 | ) | ||
Cumulative dividends for Series A Preferred Stock | (3,588 | ) | (1,576 | ) | (1,309 | ) | |||||
Cumulative dividends for Series B Preferred Stock | (3,665 | ) | - | - | |||||||
Net loss attributable to common stockholders | $ | (422,834 | ) | $ | (143,966 | ) | $ | (179,839 | ) | ||
Loss per share: | |||||||||||
Basic and diluted | $ | (6.86 | ) | $ | (24.40 | ) | $ | (73.19 | ) | ||
Condensed Consolidated Statement of Cash Flows
For the years ended
(in thousands of
Years ended |
|||||||||||
2022 | 2021 | 2020 | |||||||||
Cash flows from operating activities | |||||||||||
Net loss | $ | (415,581 | ) | $ | (142,390 | ) | $ | (178,530 | ) | ||
Adjustments to reconcile net loss | |||||||||||
Depreciation and amortization | 71,831 | 77,150 | 93,953 | ||||||||
Original issue discount and debt issuance cost amortization | 15,261 | 16,319 | 15,117 | ||||||||
Debt modification and extinguishment costs (gain), net | (1,803 | ) | (30,613 | ) | 8,296 | ||||||
Impairment of goodwill and other intangible assets | 171,182 | - | - | ||||||||
Provision for doubtful accounts | 1,573 | 2,714 | 422 | ||||||||
Deferred income tax provision | 147 | 6,649 | 7,940 | ||||||||
Share-based compensation expense | 970 | 3,940 | 2,846 | ||||||||
Unrealized foreign currency losses (gain) | (1,288 | ) | 173 | (414 | ) | ||||||
Loss (Gain) on sale of assets | 707 | (960 | ) | (43,338 | ) | ||||||
Fair value adjustment for interest rate swap | - | (125 | ) | (375 | ) | ||||||
Change in operating assets and liabilities, net of effect from acquisitions | |||||||||||
Accounts receivable | 77,650 | 17,438 | 54,538 | ||||||||
Prepaid expenses and other assets | (7,813 | ) | (1,597 | ) | (1,379 | ) | |||||
Accounts payable and accrued liabilities | (520 | ) | (61,068 | ) | 12,015 | ||||||
Related party payables | 945 | 1,382 | (353 | ) | |||||||
Additions to outsource contract costs | (423 | ) | (546 | ) | (519 | ) | |||||
Net cash used in operating activities | (87,162 | ) | (111,534 | ) | (29,781 | ) | |||||
Cash flows from investing activities | |||||||||||
Purchase of property, plant and equipment | (18,299 | ) | (14,574 | ) | (11,663 | ) | |||||
Additions to patents | (15 | ) | - | - | |||||||
Additions to internally developed software | (3,650 | ) | (1,954 | ) | (3,825 | ) | |||||
Cash paid for acquisition, net of cash received | - | - | (12,500 | ) | |||||||
Cash paid for earnouts | - | - | (700 | ) | |||||||
Proceeds from sale of assets | 194 | 7,267 | 50,126 | ||||||||
Net cash provided by (used in) investing activities | (21,770 | ) | (9,261 | ) | 21,438 | ||||||
Cash flows from financing activities | |||||||||||
Proceeds from issuance of Common Stock from private placement | 55 | 25,065 | - | ||||||||
Proceeds from issuance of Common Stock from at the market offerings | 276,337 | 379,963 | - | ||||||||
Dividend paid on Series B Preferred Stock | (2,532 | ) | - | - | |||||||
Proceeds from directors' equity contribution | - | 269 | - | ||||||||
Repurchases of Common Stock for retirement | (487 | ) | - | - | |||||||
Cash paid for equity issuance costs from at the market offerings | (9,482 | ) | (13,423 | ) | - | ||||||
Borrowings under factoring arrangement and Securitization Facility | 123,353 | 142,501 | 297,673 | ||||||||
Principal repayment on borrowings under factoring arrangement and Securitization Facility | (216,812 | ) | (144,965 | ) | (203,841 | ) | |||||
Cash paid for withholding taxes on vested RSUs | (135 | ) | - | (7 | ) | ||||||
Lease terminations | 3 | (1,303 | ) | (337 | ) | ||||||
Cash paid for debt issuance costs | (7,125 | ) | (1,181 | ) | (16,205 | ) | |||||
Principal payments on finance lease obligations | (5,523 | ) | (11,471 | ) | (12,758 | ) | |||||
Borrowings from senior secured revolving facility and BRCC revolver | 20,000 | 11,000 | 29,750 | ||||||||
Repayments on senior secured revolving facility | (49,477 | ) | (55 | ) | (14,200 | ) | |||||
Proceeds from issuance of 2026 Notes | 70,269 | 3,574 | - | ||||||||
Repayments on senior secured term loan and 2023 Notes as part of debts exchanges | - | (309,305 | ) | - | |||||||
Borrowings from other loans | 10,095 | 126,352 | 29,260 | ||||||||
Cash paid for debt repurchases | (4,712 | ) | (71,184 | ) | - | ||||||
Repayment of BRCC term loan | (66,471 | ) | - | - | |||||||
Principal repayments on senior secured term loans and other loans | (30,717 | ) | (37,186 | ) | (45,973 | ) | |||||
Net cash provided by financing activities | 106,639 | 98,651 | 63,362 | ||||||||
Effect of exchange rates on cash | (700 | ) | (105 | ) | 1,191 | ||||||
Net increase (decrease) in cash and cash equivalents | (2,993 | ) | (22,249 | ) | 56,210 | ||||||
Cash, restricted cash, and cash equivalents | |||||||||||
Beginning of period | 48,060 | 70,309 | 14,099 | ||||||||
End of period | $ | 45,067 | $ | 48,060 | $ | 70,309 | |||||
Supplemental cash flow data: | |||||||||||
Income tax payments, net of refunds received | $ | 5,790 | $ | 3,765 | $ | 2,695 | |||||
Interest paid | 98,602 | 188,802 | 152,678 | ||||||||
Noncash investing and financing activities: | |||||||||||
Assets acquired through right-of-use arrangements | 4,790 | 3,270 | 4,372 | ||||||||
Leasehold improvements funded by lessor | - | 125 | - | ||||||||
Common Stock exchanged for Series B Preferred Stock | 6 | - | - | ||||||||
Accrued liability for true-up obligation settled through the issuance of 2026 Notes | 10,351 | - | - | ||||||||
Settlement gain on related party payable to Ex-Sigma 2 LLC | - | - | 1,287 | ||||||||
Accrued capital expenditures | 1,851 | 1,652 | 2,124 | ||||||||
Schedule 1: Fourth Quarter 2022 vs. Third Quarter 2022
Financial Performance
(Unaudited)
$ in million | Q4-2022 | Q4-2021 | Increase (Decrease) YoY ($ mn) |
Increase (Decrease) YoY (%) |
FY2022 | FY2021 | Increase (Decrease) YoY ($ mn) |
Increase (Decrease) YoY (%) |
|
Information and Transaction Processing Solutions | 184.8 | 216.7 | (31.9) | (14.7%) | 765.1 | 874.2 | (109.1) | (12.5%) | |
Healthcare Solutions | 65.3 | 56.5 | 8.8 | 15.6% | 239.3 | 217.8 | 21.5 | 9.9% | |
Legal and |
16.8 | 21.1 | (4.3) | (20.4%) | 72.8 | 74.6 | (1.8) | (2.4%) | |
Total Revenue | 267.0 | 294.3 | (27.4) | -9.3% | 1,077.2 | 1,166.6 | (89.4) | -7.7% | |
Gross profit | 48.1 | 58.6 | (10.5) | (17.9%) | 199.7 | 277.5 | (77.8) | (28.0%) | |
Gross profit margin | 18.0% | 19.9% | (1.9%) | -190 bps | 18.5% | 23.8% | (5.2%) | -525 bps | |
SG&A | 38.9 | 48.3 | (9.3) | (19.4%) | 176.5 | 169.8 | 6.7 | 4.0% | |
Operating (loss) income | (153.1) | (10.7) | (142.4) | 1333.9% | (228.8) | 21.4 | (250.2) | (1169.6%) | |
Operating margin | (57.3%) | (3.6%) | (53.7%) | -5371 bps | (21.2%) | 1.8% | (23.1%) | -2307 bps | |
Net income (loss) | (194.1) | (70.6) | (123.5) | 175.0% | (415.6) | (142.4) | (273.2) | 191.9% | |
Net income margin | (72.7%) | (24.0%) | (48.7%) | -4874 bps | (38.6%) | (12.2%) | (26.4%) | -2638 bps | |
EBITDA | (135.8) | (3.1) | (132.8) | 4350.1% | (174.7) | 114.5 | (289.1) | (252.6%) | |
EBITDA Margin | (50.9%) | (1.0%) | (49.8%) | -4985 bps | (16.2%) | 9.8% | (26.0%) | -2603 bps | |
Adjusted EBITDA | 35.5 | 39.5 | (4.0) | -10.2% | 139.9 | 173.3 | (33.4) | -19.3% | |
Adjusted EBITDA margin | 13.3% | 13.4% | (0.1%) | -14 bps | 13.0% | 14.9% | (1.9%) | -187 bps | |
Schedule 2: Reconciliation of Adjusted EBITDA and constant currency revenues
Reconciliation of Non-GAAP Financial Measures to GAAP Measures | |||||||||
Non-GAAP constant currency revenue reconciliation | |||||||||
($ in millions) | Three months ended |
Twelve months ended | |||||||
Revenues, as reported (GAAP) | |||||||||
Foreign currency exchange impact (1) | 5.9 | 22.9 | |||||||
Revenues, at constant currency (Non-GAAP) | |||||||||
(1) Constant currency excludes the impact of foreign currency fluctuations and is computed by applying the average exchange rates for the three months and twelve months ended |
|||||||||
Reconciliation of Adjusted EBITDA | |||||||||
($ in millions) | Three months ended |
Twelve months ended | |||||||
Net loss (GAAP) | ( |
( |
( |
( |
|||||
Interest expense | 41.9 | 40.3 | 164.9 | 168.0 | |||||
Taxes | (1.5) | 8.2 | 4.2 | 11.7 | |||||
Depreciation and amortization | 17.9 | 19.0 | 71.8 | 77.1 | |||||
EBITDA (Non-GAAP) | ( |
( |
( |
||||||
Transaction and integration costs | 2.1 | 7.9 | 18.6 | 15.9 | |||||
Other Charges / (gains) | 163.5 | 28.1 | 271.8 | 21.6 | |||||
Sub-Total (Adj. EBITDA before O&R) | |||||||||
Optimization and restructuring expenses | 5.7 | 7.3 | 25.3 | 22.2 | |||||
Adjusted EBITDA (Non-GAAP) |
Source: Exela Technologies, Inc.